BR112016000889A2 - composição e vacina para tratamento de câncer de próstata - Google Patents

composição e vacina para tratamento de câncer de próstata

Info

Publication number
BR112016000889A2
BR112016000889A2 BR112016000889A BR112016000889A BR112016000889A2 BR 112016000889 A2 BR112016000889 A2 BR 112016000889A2 BR 112016000889 A BR112016000889 A BR 112016000889A BR 112016000889 A BR112016000889 A BR 112016000889A BR 112016000889 A2 BR112016000889 A2 BR 112016000889A2
Authority
BR
Brazil
Prior art keywords
prostate
vaccine
composition
antigens
antigen
Prior art date
Application number
BR112016000889A
Other languages
English (en)
Inventor
Kallen Karl-Josef
Fotin-Mleczek Mariola
Lander Thomas
Gnad-Vogt Ulrike
Original Assignee
Curevac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac Ag filed Critical Curevac Ag
Publication of BR112016000889A2 publication Critical patent/BR112016000889A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0091—Oxidoreductases (1.) oxidizing metal ions (1.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y116/00—Oxidoreductases oxidizing metal ions (1.16)
    • C12Y116/01—Oxidoreductases oxidizing metal ions (1.16) with NAD+ or NADP+ as acceptor (1.16.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03002—Acid phosphatase (3.1.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21077—Semenogelase (3.4.21.77), i.e. prostate specific antigen or PSA or kallikrein 3

Abstract

a presente invenção refere-se a uma composição compreendendo pelo menos um mrna que codifica uma combinação de antígenos capaz de induzir uma resposta imune (adaptiva) em uma mamífero, no qual os antígenos são selecionados a partir do grupo consistindo em psa (antígeno específico de próstata), psma (antígeno de membrana específico de próstata), psca (antígeno de célula-tronco da próstata), steap (seis antígenos epiteliais de transmembrana da próstata), muc1 (mucina 1) e pap (fosfatase ácida prostática). a invenção, além disso, se relaciona a uma vacina compreendendo pelo menos um mrna que codifica tal combinação de antígenos, e ao uso de referida composição (para a preparação de uma vacina) e/ou da vacina para indução de uma resposta imune (adaptiva) para o tratamento de câncer de próstata (pca), de preferência, de adenocarcinoma de próstata, cânceres de próstata localmente limitados, localmente avançados, metastáticos, resistentes à castração (refratário de hormônio), resistentes à castração metastáticos e resistentes à castração não metastáticos, e doenças ou distúrbios relacionados a estes. finalmente, a invenção se relaciona a kits, particularmente, a kits de partes, contendo a composição e/ou a vacina.
BR112016000889A 2013-08-21 2014-08-21 composição e vacina para tratamento de câncer de próstata BR112016000889A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2013002515 2013-08-21
EP2013002516 2013-08-21
PCT/EP2014/002297 WO2015024664A1 (en) 2013-08-21 2014-08-21 Composition and vaccine for treating prostate cancer

Publications (1)

Publication Number Publication Date
BR112016000889A2 true BR112016000889A2 (pt) 2017-12-12

Family

ID=51398599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016000889A BR112016000889A2 (pt) 2013-08-21 2014-08-21 composição e vacina para tratamento de câncer de próstata

Country Status (11)

Country Link
US (1) US20160166668A1 (pt)
JP (2) JP2016532451A (pt)
KR (1) KR20160043103A (pt)
CN (1) CN105517566A (pt)
AU (1) AU2014310930A1 (pt)
BR (1) BR112016000889A2 (pt)
CA (1) CA2915904A1 (pt)
MX (1) MX2016002153A (pt)
RU (1) RU2016109938A (pt)
SG (2) SG10201801433XA (pt)
WO (1) WO2015024664A1 (pt)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4074693A1 (en) 2011-06-08 2022-10-19 Translate Bio, Inc. Cleavable lipids
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
SG10201710472PA (en) 2013-02-22 2018-02-27 Curevac Ag Combination of vaccination and inhibition of the pd-1 pathway
WO2015024669A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Combination vaccine
RU2723328C2 (ru) 2013-08-21 2020-06-09 Куревак Аг Вакцина против респираторно-синцитиального вируса (рсв)
RU2733424C2 (ru) 2013-08-21 2020-10-01 Куревак Аг Способ повышения экспрессии кодируемых рнк белков
CN110195072A (zh) 2013-08-21 2019-09-03 库瑞瓦格股份公司 狂犬病疫苗
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
JP6584414B2 (ja) 2013-12-30 2019-10-02 キュアバック アーゲー 人工核酸分子
SG10201805660WA (en) 2013-12-30 2018-08-30 Curevac Ag Methods for rna analysis
US10369216B2 (en) 2014-04-01 2019-08-06 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
ES2727776T3 (es) 2014-06-10 2019-10-18 Curevac Ag Método para mejorar la producción de ARN
PL3766916T3 (pl) 2014-06-25 2023-02-27 Acuitas Therapeutics Inc. Nowe lipidy i formulacje nanocząstek lipidowych do dostarczania kwasów nukleinowych
WO2016091391A1 (en) 2014-12-12 2016-06-16 Curevac Ag Artificial nucleic acid molecules for improved protein expression
EP4353257A2 (en) 2015-04-13 2024-04-17 CureVac Manufacturing GmbH Method for producing rna compositions
SG11201707663SA (en) 2015-04-17 2017-11-29 Curevac Ag Lyophilization of rna
RU2749113C2 (ru) 2015-04-22 2021-06-04 Куревак Аг Содержащая рнк композиция для лечения опухолевых заболеваний
WO2016174271A1 (en) 2015-04-30 2016-11-03 Curevac Ag Immobilized poly(n)polymerase
DK3294885T3 (da) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh Fremgangsmåde til at fremstille rna
MX2017014538A (es) 2015-05-15 2018-03-02 Curevac Ag Regimenes de cebado-refuerzo que implican la administracion de al menos un constructo de arnm.
EP3928800A3 (en) 2015-05-20 2022-03-23 CureVac AG Dry powder composition comprising long-chain rna
US10517827B2 (en) 2015-05-20 2019-12-31 Curevac Ag Dry powder composition comprising long-chain RNA
US11608513B2 (en) 2015-05-29 2023-03-21 CureVac SE Method for adding cap structures to RNA using immobilized enzymes
DE202016009003U1 (de) 2015-05-29 2021-05-28 Curevac Real Estate Gmbh Zusammensetzung umfassend in vitro transkribierte RNA erhältlich durch ein Verfahren zur Herstellung und Reinigung von RNA mit mindestens einem Schritt mit einer tangentialen Flussfiltration
CN105985984B (zh) * 2015-06-17 2018-10-02 深圳益世康宁生物科技有限公司 携带pap抗原基因的重组腺相关病毒载体及构建方法与应用
CN105087649B (zh) * 2015-06-17 2018-10-02 深圳益世康宁生物科技有限公司 携带muc-1抗原基因的重组腺相关病毒载体及构建方法与应用
US10221127B2 (en) 2015-06-29 2019-03-05 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017009376A1 (en) 2015-07-13 2017-01-19 Curevac Ag Method of producing rna from circular dna and corresponding template dna
AU2016324310B2 (en) 2015-09-17 2021-04-08 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3362576A1 (en) 2015-10-12 2018-08-22 CureVac AG Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017066781A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
EP3362460A1 (en) 2015-10-16 2018-08-22 Modernatx, Inc. Mrna cap analogs and methods of mrna capping
AU2016343803B2 (en) 2015-10-28 2021-04-29 Acuitas Therapeutics, Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017081110A1 (en) 2015-11-09 2017-05-18 Curevac Ag Rotavirus vaccines
WO2017109134A1 (en) 2015-12-22 2017-06-29 Curevac Ag Method for producing rna molecule compositions
JP7114465B2 (ja) 2015-12-22 2022-08-08 モデルナティエックス インコーポレイテッド 薬剤の細胞内送達のための化合物および組成物
EP3394280A1 (en) 2015-12-23 2018-10-31 CureVac AG Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
WO2017140905A1 (en) 2016-02-17 2017-08-24 Curevac Ag Zika virus vaccine
WO2017149139A1 (en) 2016-03-03 2017-09-08 Curevac Ag Rna analysis by total hydrolysis
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
US11141474B2 (en) 2016-05-04 2021-10-12 Curevac Ag Artificial nucleic acid molecules encoding a norovirus antigen and uses thereof
WO2017203008A1 (en) 2016-05-25 2017-11-30 Curevac Ag Novel biomarkers
CA3026342A1 (en) * 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
WO2017212009A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
WO2017218704A1 (en) 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN106119231A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种肿瘤抗原psa的ctl识别表位肽及其应用
JOP20190067A1 (ar) * 2016-09-30 2019-03-28 Janssen Pharmaceutica Nv طُرق تشخيص وعلاج سرطان البروستاتا النقيلي المقاوم للإخصاء والمقاوم أو الحساس لأبيراتيرون أسيتات-الهرمون القشري السكري
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
US11464836B2 (en) 2016-12-08 2022-10-11 Curevac Ag RNA for treatment or prophylaxis of a liver disease
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
EP3558354A1 (en) 2016-12-23 2019-10-30 CureVac AG Lassa virus vaccine
WO2018115507A2 (en) 2016-12-23 2018-06-28 Curevac Ag Henipavirus vaccine
US11141476B2 (en) 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
TW201842921A (zh) 2017-02-28 2018-12-16 法商賽諾菲公司 治療性ｒｎａ
AU2018234692B2 (en) 2017-03-15 2022-06-02 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
EP3601576A1 (en) 2017-03-24 2020-02-05 CureVac AG Nucleic acids encoding crispr-associated proteins and uses thereof
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
WO2018200975A1 (en) 2017-04-27 2018-11-01 Vanderbilt University Hepatitis c virus gene sequences and methods of use therefor
JP7297676B2 (ja) 2017-04-28 2023-06-26 アクイタス セラピューティクス インコーポレイテッド 新規なカルボニル脂質、および核酸を送達するための脂質ナノ粒子製剤
EP3638678A1 (en) 2017-06-14 2020-04-22 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
BR112019028280A2 (pt) 2017-07-04 2020-07-14 Curevac Ag moléculas de ácido nucleico
US11639329B2 (en) 2017-08-16 2023-05-02 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036638A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR PREPARING MODIFIED RNA
WO2019038332A1 (en) 2017-08-22 2019-02-28 Curevac Ag VACCINE AGAINST BUNYAVIRUS
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
WO2019077001A1 (en) 2017-10-19 2019-04-25 Curevac Ag NEW ARTIFICIAL NUCLEIC ACID MOLECULES
CA3078292A1 (en) * 2017-10-20 2019-04-25 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy
JP2021502079A (ja) 2017-11-08 2021-01-28 キュアバック アーゲー ＲＮＡ配列の適合（Ａｄａｐｔａｔｉｏｎ）
US11931406B2 (en) 2017-12-13 2024-03-19 CureVac SE Flavivirus vaccine
US11525158B2 (en) 2017-12-21 2022-12-13 CureVac SE Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA
JP7410135B2 (ja) 2018-09-19 2024-01-09 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のための化合物及び組成物
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
SG11202108098QA (en) 2019-01-31 2021-08-30 Modernatx Inc Vortex mixers and associated methods, systems, and apparatuses thereof
CA3128215A1 (en) 2019-01-31 2020-08-06 Modernatx, Inc. Methods of preparing lipid nanoparticles
US20230114808A1 (en) * 2019-03-12 2023-04-13 BioNTech SE Therapeutic rna for prostate cancer
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
TW202204622A (zh) 2020-04-09 2022-02-01 大陸商蘇州艾博生物科技有限公司 針對冠狀病毒之核酸疫苗
EP4077272A1 (en) 2020-04-09 2022-10-26 Suzhou Abogen Biosciences Co., Ltd. Lipid nanoparticle composition
WO2021209897A1 (en) * 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
KR20230030588A (ko) 2020-06-30 2023-03-06 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 지질 화합물 및 지질 나노입자 조성물
IL298993A (en) * 2020-07-07 2023-02-01 BioNTech SE Therapeutic RNA for HPV positive cancer
KR20230054672A (ko) 2020-08-20 2023-04-25 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 지질 화합물 및 지질 나노입자 조성물
CA3205569A1 (en) 2020-12-22 2022-06-30 CureVac SE Rna vaccine against sars-cov-2 variants
WO2022152109A2 (en) 2021-01-14 2022-07-21 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CN116615472A (zh) 2021-01-14 2023-08-18 苏州艾博生物科技有限公司 聚合物缀合的脂质化合物和脂质纳米颗粒组合物
WO2022247755A1 (en) 2021-05-24 2022-12-01 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
WO2023044333A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Cyclic lipids and methods of use thereof
CA3231523A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Acyclic lipids and methods of use thereof
AR127312A1 (es) 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
AU2022358824A1 (en) 2021-10-08 2024-04-11 Suzhou Abogen Biosciences Co., Ltd. Lipid compounds and lipid nanoparticle compositions
CN116064598B (zh) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
WO2023196931A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
WO2024037578A1 (en) 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
TW201204410A (en) * 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
AU2005270430B2 (en) * 2004-08-03 2008-06-12 Geneart Ag Method for modulating gene expression by modifying the CpG content
EP2366400B1 (en) * 2005-06-28 2015-09-30 Oncothyreon Inc. Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
WO2009046738A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
GB2484058A (en) * 2009-12-01 2012-04-04 Uni Konstanz Prostate cancer DNA vaccine
WO2012019630A1 (en) * 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012116715A1 (en) * 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012116714A1 (en) * 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients

Also Published As

Publication number Publication date
RU2016109938A (ru) 2017-09-26
AU2014310930A1 (en) 2016-01-21
US20160166668A1 (en) 2016-06-16
JP2016532451A (ja) 2016-10-20
CA2915904A1 (en) 2015-02-26
MX2016002153A (es) 2017-03-01
WO2015024664A1 (en) 2015-02-26
KR20160043103A (ko) 2016-04-20
RU2016109938A3 (pt) 2018-03-28
CN105517566A (zh) 2016-04-20
JP2018184422A (ja) 2018-11-22
SG11201510751YA (en) 2016-03-30
SG10201801433XA (en) 2018-04-27

Similar Documents

Publication Publication Date Title
BR112016000889A2 (pt) composição e vacina para tratamento de câncer de próstata
CO2019006914A2 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
BR112017017293A2 (pt) método para predizer modificações de aminoácidos, para selecionar e/ou classificar modificações de aminoácidos e para fornecer uma vacina e vacina
BR112019001922A2 (pt) receptores de célula t e imunoterapia usando os mesmos
EA201791150A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
CR20190278A (es) Nuevos receptores de células t y terapia inmunológica que los utiliza
BR112016003400A2 (pt) composição e vacina para tratamento de câncer de pulmão
BR112013029834A8 (pt) vacinas individualizadas para câncer
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
EA201690868A1 (ru) Персонализированная иммунотерапия нескольких видов нейрональных опухолей и опухолей головного мозга
EA200900795A1 (ru) Вакцина
BR112015029953A2 (pt) anticorpos anti-tweakr e seus usos
BR112012013915A8 (pt) anticorpos anti-c4. 4a e usos dos mesmos
BR112017003472A2 (pt) anticorpos, fragmento fab de anticorpo e método para o tratamento de uma doença inflamatória
CY1123520T1 (el) Μεθοδοι για την προβλεψη της χρησιμοτητας των νεων αντιγονων για ανοσοθεραπεια
PL422231A1 (pl) Komórki immunologiczne CAR do leczenia nowotworów
BR112022009100A2 (pt) Peptídeos antigênicos para prevenção e tratamento de malignidade de células b
CY1124685T1 (el) Εξατομικευμενα εμβολια για τον καρκινο
BR112017022205A2 (pt) anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada
CY1124813T1 (el) Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του ηπατοκυτταρικου καρκινωματος (hcc) και αλλων μορφων καρκινου
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
CO6420322A2 (es) Anticuerpos anti-mst1r y usos de los mismos
CO2020000231A2 (es) Composiciones inmunogénicas que comprenden cea muc1 y tert
PH12018501532A1 (en) Cancer vaccines

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2529 DE 25-06-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]